What insurance does a CLIA-certified clinical laboratory need?

CLIA-certified clinical, molecular, and diagnostic laboratories operate under a specific Clinical Laboratory Improvement Amendments (CLIA) regulatory framework that creates distinct insurance exposures from general medical practice or pharma manufacturing. The four core coverage lines structural for any CLIA lab at commercial scale: professional liability for testing accuracy claims, cyber/HIPAA for PHI handling, products liability for any laboratory-developed tests (LDTs), and property coverage sized to specialized instrument replacement values.

A fifth line — professional liability for clinical interpretation services — applies to labs that offer interpretation or advisory services beyond the basic test result reporting. This is increasingly common in molecular and genomic labs where the test result requires clinical context to be actionable.

Clinical lab professional liability covers economic loss and bodily injury arising from inaccurate test results: false positives that led to unnecessary treatment, false negatives that missed a treatable condition, mislabeled samples that produced wrong-patient diagnoses, contamination that compromised batch test integrity. The trigger is the test accuracy failure; the harm flows to the patient (through clinical mismanagement) and to the ordering provider (through liability exposure).

Sizing typically starts at $1M-$3M per claim for smaller labs and scales with test volume and acuity. Reference laboratories handling high-acuity tests (oncology biomarkers, prenatal genetic testing, infectious disease diagnostics) routinely carry $5M-$10M professional liability because the severity tail on a misdiagnosis is correspondingly higher.

CLIA labs handle protected health information (PHI) at scale — patient demographic data, ordering provider data, test results, and increasingly genomic data — across a wide downstream distribution to ordering providers, payers, and patient portals. The PHI volume drives cyber sizing.

For a mid-size molecular or clinical lab handling 50,000+ tests annually with EHR integration to ordering providers and a patient portal, $2M-$5M cyber liability is the typical starting point. Larger reference laboratories handling millions of tests annually scale to $10M-$25M cyber. Coverage scope should include first-party breach response, third-party liability for breach claims, regulatory defense for HIPAA enforcement actions, and ransomware payment coverage where state law permits.

State-law privacy claims layered on top of HIPAA — CCPA, MHMDA, BIPA (for biometric/genomic data), CTDPA, MPIPA, CMIA — extend cyber exposure in many jurisdictions. Genomic and biomarker labs face particular BIPA exposure in Illinois operations.

Laboratory-developed tests (LDTs) — tests designed, manufactured, and used within a single laboratory — have historically operated under FDA enforcement discretion but face an evolving regulatory environment. FDA's 2024 Final Rule on LDT regulation phased in product oversight for high-risk LDTs over a four-year period beginning in 2025.

CLIA labs offering LDTs at commercial scale now face products liability exposure for the LDT itself in addition to professional liability for test execution. The two coverages overlap partially but cover different harms — products liability for the LDT as a product, professional liability for the lab's test-performance services. Standalone products liability at $1M-$5M is structural for any CLIA lab with material LDT revenue.

CLIA labs operate with specialized analytical instruments — mass spectrometers, automated immunoassay analyzers, next-generation sequencing platforms, flow cytometers, real-time PCR systems — that frequently cost $200K-$2M per instrument. Replacement-cost property coverage at full instrument value, plus business interruption sized to the time-to-replace window (often 90-180 days for high-end instruments), is structural.

Equipment breakdown coverage adds protection for mechanical and electrical failures that property policies sometimes exclude. For a lab with multiple high-value automated systems, equipment breakdown is typically a $5,000-$15,000 annual premium add that pays for itself on a single instrument failure.

Labs that offer clinical interpretation or advisory services beyond basic test reporting — molecular labs providing variant interpretation, genomic labs providing inherited-risk consultations, biomarker labs providing therapy-selection recommendations — face professional liability exposure on the interpretation in addition to the testing accuracy exposure.

A standalone clinical interpretation E&O at $1M-$3M is structural for any lab with material interpretation services revenue. The coverage parallels physician professional liability in structure but is priced for the lab's contractual scope rather than direct clinical encounter exposure.

For a Texas CLIA lab in the $5M-$20M revenue range: combined professional liability + cyber + products (LDT) + property + workers comp + auto + umbrella typically runs $40,000-$120,000 annual depending on test mix, instrument inventory, LDT revenue concentration, and PHI volume. Professional liability and cyber drive most of the premium; property and workers comp are modest unless instrument inventory is unusually high.